nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Advanced solid tumors often present with hepatic dysfunction, complicating treatment.
• Paclitaxel, a common chemotherapy agent, requires dose adjustments in patients with impaired liver function.
• Albumin-bound paclitaxel (nab-paclitaxel) offers an alternative formulation with potentially different pharmacokinetic properties.

Purpose of the Study:

• To evaluate the safety and pharmacokinetics of nab-paclitaxel in patients with advanced solid tumors and hepatic dysfunction.
• To determine the tolerability of nab-paclitaxel across different dose levels in this specific patient population.
• To assess the correlation between liver function parameters and nab-paclitaxel clearance.

Main Methods:

• Pilot, open-label clinical study design.
• Dosing of nab-paclitaxel (130, 200, or 260 mg/m(2) every 3 weeks) based on baseline bilirubin levels.
• Monitoring of adverse events, including neutropenia, fatigue, neuropathy, and liver function tests.

Main Results:

• Thirty patients with elevated bilirubin and AST received nab-paclitaxel.
• Most common grade 3/4 adverse events were neutropenia and fatigue.
• Treatment-related bilirubinemia and elevated AST were observed, with inverse correlation between total bilirubin and paclitaxel clearance (p < 0.001).

Conclusions:

• Nab-paclitaxel exhibits an acceptable safety profile in patients with solid tumors and hepatic dysfunction.
• The observed safety and pharmacokinetic data support existing dose modification guidelines for paclitaxel.
• Nab-paclitaxel represents a viable treatment option for this patient cohort, warranting further investigation.